EFFECT OF PREOPERATIVE ADMINISTRATION OF DUTASTERIDE ON REDUCING BLOOD LOSS IN PERIOPERATIVE PERIOD OF TRANSURETHRAL RESECTION OF PROSTATE

Abstract

AbstractBackground and Objective: Clinical benign prostatic hyperplasia (BPH), a condition that commonly occurs inaging men. It is characterized by the development of lower urinary tract symptoms (LUTS), which can lead toimpairment of bladderfunction and potentialrenal complications.TURPisthe gold standard surgical treatmentof BPH. Dutasteride is a 5-reductase and is used for medical management. This study was planned toascertain the effect of pre-treatment dutasteride in reducing blood loss in patients undergoing transurethralresection of prostate (TURP).Methods: It was a randomized clinical trial carried out at Department of Urology, Jinnah Hospital Lahore inwhich the total study sample was divided in two groups. One group received dutasteride and the second groupwas the control group. The study variables were Haemoglobin and Hematocrit values, clotting profile PTandINR, serum Ca levels and uric acid, BMI, prostate volume, residual volume of urine and hospital stay. Resultswere presented as mean ± SD or frequency (%). The main study outcome variable was mean blood loss(calculated by change in hemoglobin and hematocrit level).Results: 6 (10.3 %) patients needed blood transfusion in dutasteride group and 7 (12 %) in control group(p=0.14). Post-surgery change in haemoglobin and HCT levels were less in dutasteride groups as comparedto the control group (ΔHb 1.94±1.27 g/dLvs. 2.16±0.73 g/dL, respectively, p=0.02;ΔHct 5.68 % ± 2.56% vs.6.52 % ± 2.39 %, respectively, p = 0.04).Conclusion: Thepresentresearchsuggeststhat administeringDutasteride fourweekspriortotheTURPprocedureresultsinadecreaseinbloodlossduringtheperi-operativeperiod,ultimatelyleadingtoimprovedpatientoutcomes.Key words: Benign Prostatic Hyperplasia (BPH). Transurethral resection of Prostate (TURP), 5 AlphaReductase Inhibitor (5-ARI)